Detected ·
Sling Therapeutics
$123M—
Sling Therapeutics raised a $123M Series C led by Forbion to advance linsitinib, an oral IGF-1R inhibitor for thyroid eye disease, and launch its Phase 3 ORBIT trial.
- Website
- slingtx.com
- linkedin.com/company/sling-tx
- Amount
- $123 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-09-16 12:06:34 UTC
- Signal ID
- d430592d-d5ca-4fa5-952f-ec879c43b5c0
As the API returns it
{
"id": "d430592d-d5ca-4fa5-952f-ec879c43b5c0",
"created_at": "2026-09-16T12:06:34.009251Z",
"company_name": "Sling Therapeutics",
"company_website_url": "slingtx.com",
"company_linkedin_url": "https://www.linkedin.com/company/sling-tx",
"event_type": "funding",
"funding_amount": 123000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Sling Therapeutics raised a $123M Series C led by Forbion to advance linsitinib, an oral IGF-1R inhibitor for thyroid eye disease, and launch its Phase 3 ORBIT trial.*"
}